127 related articles for article (PubMed ID: 15714432)
1. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia.
Oren I
Clin Infect Dis; 2005 Mar; 40(5):770-1. PubMed ID: 15714432
[No Abstract] [Full Text] [Related]
2. Breakthrough invasive pulmonary aspergillosis despite empirical voriconazole therapy for febrile neutropenia: case report and review of the literature.
Meyer M; Waldvogel S; Chalandon Y; Bongiovanni M; Pache JC; Van Delden C
Scand J Infect Dis; 2007; 39(8):731-3. PubMed ID: 17654353
[TBL] [Abstract][Full Text] [Related]
3. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
4. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
5. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required.
Vigouroux S; Morin O; Moreau P; Méchinaud F; Morineau N; Mahé B; Chevallier P; Guillaume T; Dubruille V; Harousseau JL; Milpied N
Clin Infect Dis; 2005 Feb; 40(4):e35-7. PubMed ID: 15712069
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
Ullmann AJ; Heussel CP; Cornely OA
N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041526
[No Abstract] [Full Text] [Related]
7. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
Apisarnthanarak A; Little JR; Tebas P
N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041527
[No Abstract] [Full Text] [Related]
8. Breakthrough zygomycosis and voriconazole.
Pagano L; Gleissner B; Fianchi L
J Infect Dis; 2005 Oct; 192(8):1496-7; author reply 1497. PubMed ID: 16170771
[No Abstract] [Full Text] [Related]
9. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?
Pongas GN; Lewis RE; Samonis G; Kontoyiannis DP
Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():93-7. PubMed ID: 19754766
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia.
Al-Badriyeh D; Liew D; Stewart K; Kong DC
J Antimicrob Chemother; 2009 Jan; 63(1):197-208. PubMed ID: 19001450
[TBL] [Abstract][Full Text] [Related]
11. Treating disseminated fusariosis: amphotericin B, voriconazole or both?
Ho DY; Lee JD; Rosso F; Montoya JG
Mycoses; 2007 May; 50(3):227-31. PubMed ID: 17472622
[TBL] [Abstract][Full Text] [Related]
12. Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever.
Powers JH; Dixon CA; Goldberger MJ
N Engl J Med; 2002 Jan; 346(4):289-90. PubMed ID: 11807157
[No Abstract] [Full Text] [Related]
13. Early fatal Rhizopus infection on voriconazole prophylaxis following allogeneic stem cell transplantation.
Ustun C; Farrow S; DeRemer D; Fain H; Jillella AP
Bone Marrow Transplant; 2007 Jun; 39(12):807-8. PubMed ID: 17438583
[No Abstract] [Full Text] [Related]
14. Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child.
Ritz N; Ammann RA; Aebischer CC; Gugger M; Jaton K; Schmid RA; Aebi C
Eur J Pediatr; 2005 Apr; 164(4):231-5. PubMed ID: 15633048
[TBL] [Abstract][Full Text] [Related]
15. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.
Marty FM; Cosimi LA; Baden LR
N Engl J Med; 2004 Feb; 350(9):950-2. PubMed ID: 14985500
[No Abstract] [Full Text] [Related]
16. Empirical antifungal therapy--new options, new tradeoffs.
Marr KA
N Engl J Med; 2002 Jan; 346(4):278-80. PubMed ID: 11807153
[No Abstract] [Full Text] [Related]
17. Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of febrile neutropenia in Australia.
Al-Badriyeh D; Liew D; Stewart K; Kong DC
Mycoses; 2012 May; 55(3):244-56. PubMed ID: 21790799
[TBL] [Abstract][Full Text] [Related]
18. Breakthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis.
Cudillo L; Girmenia C; Santilli S; Picardi A; Dentamaro T; Tendas A; de Fabritiis P
Clin Infect Dis; 2005 Apr; 40(8):1212-3. PubMed ID: 15791530
[No Abstract] [Full Text] [Related]
19. Lack of efficacy of voriconazole therapy in 2 patients with pulmonary fungus balls.
Gutierrez F; Masia M; Ramos JM; Elia M; Rodriguez-Tudela JL; Cuenca-Estrella M
Clin Infect Dis; 2005 Jun; 40(11):1706-7. PubMed ID: 15889381
[No Abstract] [Full Text] [Related]
20. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.
Siwek GT; Dodgson KJ; de Magalhaes-Silverman M; Bartelt LA; Kilborn SB; Hoth PL; Diekema DJ; Pfaller MA
Clin Infect Dis; 2004 Aug; 39(4):584-7. PubMed ID: 15356827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
